Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: Marked improvement in depletion of circulating autoantibodies

Archives of Dermatology

Volumn 144, Issue 5, 2008, Pages 658-661

  Czernik, Annette ^a   Bystryn, Jean Claude ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; DAPSONE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID;

AGED; ARTICLE; BULLOUS PEMPHIGOID; CASE REPORT; COMBINATION CHEMOTHERAPY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG POTENTIATION; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED; AUTOANTIBODIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; PEMPHIGOID, BULLOUS; PREDNISONE; TREATMENT OUTCOME;

EID: 44249126759     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.144.5.658     Document Type: Article

References (20)

1. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291(19):2367-2375.
2. Godeau B, Chevret S, Varet B, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomized, multicentre trial. Lancet. 2002;359(9300):23-29.
3. Jolles S. A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders. Clin Exp Dermatol. 2001;26(2):127-131.
4. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immunoglobulin. N Engl J Med. 2006;355(17):1772-1779.
5. Engineer L, Ahmed AR. Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: analysis of current data. J Am Acad Dermatol. 2001;44(1):83-88.
6. Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol. 2001;45(6):825-835.
7. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin. N Engl J Med. 2001;345(10):747-755.
8. Bystryn JC, Rudolph JL. IVIg treatment of pemphigus: how it works and how to use it. J Invest Dermatol. 2005;125(6):1093-1098.
9. Yu Z, Lennon VA. Mechanism of intravenous immunoglobulin therapy in antibody-mediated autoimmune diseases. N Engl J Med. 1999;340(3):227-228.
10. Tan-Lim R, Bystryn JC. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol. 1990;22(1):35-40.
11. Bystryn JC, Schenkein I, Uhr JW. A model for the regulation of antibody synthesis by serum antibody. In: Amos B, ed. Progress in Immunology. Vol 1. New York, NY: Academic Press; 1971:627.
12. Bystryn JC. Plasmapheresis therapy of pemphigus. Arch Dermatol. 1988;124(11):1702-1704.
13. Auerbach R, Bystryn JC. Plasmapheresis and immunosuppressive therapy: effect on levels of intercellular antibodies in pemphigus vulgaris. Arch Dermatol. 1979;115(6):728-730.
14. Fine JD, Appell ML, Green LK, Sams WM. Pemphigus vulgaris: combined treatment with intravenous corticosteroid pulse therapy, plasmapheresis, and azathioprine. Arch Dermatol. 1988;124(2):236-239.
15. Beckers RC, Brand A, Vermeer BJ, Boom BW. Adjuvant high dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Br J Dermatol. 1995;133(2):289-293.
16. Bewley AP, Keefe M. Successful treatment of pemphigus vulgaris by pulsed intravenous immunoglobulin therapy. Br J Dermatol. 1996;135(1):128-129.
17. Wever S, Zillikens D, Brocker EB. Successful treatment of refractory mucosal lesions of pemphigus vulgaris using intravenous gammaglobulin as adjuvant therapy. Br J Dermatol. 1996;135(5):862-863.
18. Tappeiner G, Steiner A. High-dosage intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid. J Am Acad Dermatol. 1989;20(4):684-685.
19. Messer G, Sizmann N, Feucht J, Meurer M. High-dose intravenous immunoglobulins for immediate control of severe pemphigus vulgaris. Br J Dermatol. 1995;133(6):1014-1016.
20. Sami N, Bhol KC, Ahmed RA. Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. Eur J Dermatol. 2003;13(4):377-381.